INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology ...
Gastric and colorectal cancers present significant therapeutic challenges, particularly in the elderly population, who often have comorbidities and diminished tolerance to standard treatments. This ...
BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
Welcome to the Intensity Therapeutics Discovery Lancet Discovery Group eBioMedicine Publication Webinar. [Operator Instructions] Please also note today's event is being recorded. I would now like to ...
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) – A new study presented today reports encouraging long-term survival outcomes from an experimental viral immunotherapy, CAN-2409, in ...
Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is ...
Krystal Biotech has suspended a study of a skin cancer therapy called KB707, citing a shift in the approach toward drug approvals by the regulatory agency. Fierce Biotech: Krystal Discontinues ...
A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options. Findings from the QB46C-H07 phase 2a clinical trial ...
ST. LOUIS--(BUSINESS WIRE)--Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback